Study of 830,000 Reveals No Dementia Benefit from New Bladder Drugs

A comprehensive study finds that newer medications for overactive bladder do not reduce dementia risk compared to older alternatives.

A
Aapla Nagpur Desk
19 Nov 2026, 3:32 AM IST · 2 min read
Source: Medicaldaily
Study of 830,000 Reveals No Dementia Benefit from New Bladder Drugs
KEY TAKEAWAYS
1

Newer beta-3 agonists show no lower dementia rates than older anticholinergics.

2

The study analyzed health records of over 830,000 adults aged 40-90.

3

Patients should consult healthcare providers before changing medications.

A recent study published on November 6 in JAMA Network Open has found that newer medications for overactive bladder, specifically beta-3 agonists like mirabegron and vibegron, do not offer any advantage in reducing dementia risk compared to traditional anticholinergic drugs. This research, which included a vast dataset of 830,393 adults, highlights the ongoing debate regarding the safety of these medications for older patients, particularly women, who frequently rely on them to manage urinary urgency and leakage.

The research was conducted by the Urology Institute at University Hospitals Cleveland Medical Center, utilizing the Epic Cosmos electronic health record database to track patients aged 40 to 90 who were newly prescribed treatment for overactive bladder between 2012 and 2025. The median age of the participants was 67, with a significant majority being women. The study categorized patients based on the first medication they received, revealing that approximately 572,000 were prescribed high-risk anticholinergics, while around 208,000 received beta-3 agonists.

Out of the total participants, dementia developed in 65,134 individuals, representing 7.8% of the cohort. Notably, the high-risk anticholinergic group exhibited a 10% lower hazard of developing dementia compared to those on beta-3 agonists after adjusting for various factors. The findings indicate that the estimated 10-year dementia risk was 20% for beta-3 agonists, 19% for low-risk anticholinergics, and 18.1% for high-risk anticholinergics, with one exception being younger women who showed a 20% higher risk with low-risk anticholinergics.

The implications of this study are significant for the millions of older adults managing overactive bladder symptoms, as many have been encouraged to switch to newer, more expensive medications due to concerns about dementia. However, the observational nature of the study does not establish a definitive cause-and-effect relationship regarding the safety of either drug class for cognitive health. The researchers also noted that the condition of overactive bladder itself might be an early indicator of cognitive decline, complicating the interpretation of the results.

Looking ahead, healthcare professionals emphasize the importance of individualized treatment plans for patients dealing with overactive bladder. Patients are advised not to make changes to their medication regimen without consulting their healthcare provider. Additionally, alternative treatments such as bladder training, pelvic floor therapy, and lifestyle modifications should be considered alongside medication options to manage symptoms effectively.

💬What did you think of this story?What did you think?

Read Next

No Dementia Advantage from New Bladder Drugs